Business Wire

Sharjah Ruler Launches First 17 Volumes of ‘Historical Corpus of the Arabic Language’

3.11.2021 18:21:00 EET | Business Wire | Press release

Share

A historical cultural feat for the Arab world has been attained, as His Highness Sheikh Dr. Sultan bin Muhammad Al Qasimi, Member of the Supreme Council and Ruler of Sharjah, released the first 17 volumes of the Historical Corpus of the Arabic Language – the first-of-its kind project to chronicle 17 centuries of development in the Arabic language, in the presence of His Highness Sheikh Sultan bin Ahmed Al Qasimi, Crown Prince and Deputy Ruler of Sharjah.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211103005884/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

HH Ruler of Sharjah signs the copies of ‘Historical Corpus of the Arabic Language’ at the Sharjah International Book Fair (Photo: AETOSWire)

The Corpus volumes were unveiled by the Sharjah Ruler during the opening ceremony of the 40th edition of the Sharjah International Book Fair (SIBF) on Tuesday (2 November) at Expo Centre Sharjah, in the presence of a host of Arab ministers, presidents of Arabic language academies in the region and several Arabic scholars and researchers. HH Ruler of Sharjah also unveiled the official website of The Historical Corpus of the Arabic Language on this occasion.

In his keynote address, the Sharjah Ruler noted: “Arabic is one of the oldest living languages. We are here to celebrate Arabic language experts who gathered to work for years to document the roots and meanings of the Arabic language alphabet. We have started to work hard and bridge the gaps that existed in the documentation of the language. Finally, the sun has risen on this beautiful Corpus, which is the fruit of the efforts of a number of Arabic language institutions across the region.”

He added: “The role this detailed corpus will play in informing and educating students, researchers, and linguists and even the everyday language enthusiasts will be immense. I am not exaggerating when I say that there has been no other project that has attracted my attention or the attention of the Arab linguist community in our region to the extent that this project has. I am following up on the development of the efforts of everyone involved in this project, and I assure you that in the coming years we will be publishing several more volumes. I thank each and everyone involved in making this project a success.”

The Sharjah Ruler spoke about the online platform and smart phone applications that have been designed to make the Historical Corpus available digitally, and facilitate easy access to these resources from anywhere in the world. He also signed the copies of the first edition of the Historical Corpus of the Arabic Language at the SIBF 2021 opening ceremony.

The first volumes of the corpus are dedicated to the first five Arabic letters: the Hamza, ba, ta, tha and jeem and outline their evolution throughout the pre-Islamic period, the Islamic era from 1 AH to 132 AH, the Abbasid Caliphate from 133 AH to 656 AH, and the modern-day era from 1214 AH to date.

Dedicated website

The website dedicated to the Historical Corpus of the Arabic Language will offer scholars, linguists, researchers and language enthusiasts access to the 17 volumes of the corpus from anywhere in the world.

Champions of the Arabic language from across the region joined hands

The corpus has seen the collaboration of hundreds of researchers and linguists, editors and experts from 10 Arabic language academies across the Arab world, under the supervision of the Union of Arab Scientific Language Academies in Cairo, Egypt, and with the Arabic Language Academy in Sharjah managing the project’s executive committee. The corpus relies on a database of sources collected and digitised over the last four years, comprising 20,000 Arabic books, manuscripts, sources, and historical documents, including old inscriptions and archaeological finds.

The Historical Corpus of the Arabic Language is dedicated to providing key information about the history of Arabic lexicon, the original root of each word and all other words that are derived from the root with their vocal and phonetic changes. It traces the history of a given word and identifies the first user and evolution of that word from pre-Islamic Arabia all the way to the modern time. In this respect, it is different from any other dictionary because it cites living verses of the Holy Quran and Hadith of the Prophet, peace be upon him.

It also reveals the development of Arabic idioms and expressions through the centuries, and documents the entry of new words into Arabic language, lists words that are no longer used, and explains the reasons why. Besides, the corpus reviews the development of arts and sciences that directly relate to linguistics including grammar, morphology, philology, phonetics, rhetoric, rhyme, and so on.

It also offers comparative lexical reviews on Arabic and the influence it had on other Semitic languages such as Hebrew, Akkadian, Syriac, Abyssinian, and Amharic. An expert committee outlined the similarities and differences between Arabic words and the equivalent words in those languages, citing examples and documenting the bibliography and reference books that were used in the project.

Several senior officials were present during the launch, including Sheikh Nahyan bin Mubarak Al Nahyan, UAE Minister of Tolerance and Coexistence; Bodour Al Qasimi, President of the International Publishers Association; Sheikha Hoor Al Qasimi, President of the Sharjah Art Foundation; Sheikh Khalid bin Issam Al Qasimi, Chairman of the Department of Civil Aviation in Sharjah; Sheikh Salem bin Abdulrahman Al Qasimi, Chairman of the Sharjah Ruler's Office; Sheikha Nawar bint Ahmed Al Qasimi, Director, SAF; Abdul Rahman bin Mohammad Al Owais, UAE Minister of Health and Prevention.

The launch of the corpus’s 17 volumes was also witnessed by Dr. Salah Fadl, President of the Arab Language Academy in Cairo; Dr. Mamoun Wajeeh, Scientific Manager of the Historical Corpus of the Arabic Language; Dr. Abdulhamid Madkour, Secretary General of the Union of Arab Scientific Language Academies, and Secretary-General of the Arabic Language Academy in Cairo.

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Hussain Al Mulla
Email: hussain.almulla@sgmb.ae
Phone: +97156 3980067

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye